NCT04188548 A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04185883 Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04185831 A MolEcularly Guided Anti-Cancer Drug Off-Label Trial Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04066114 Treg Modulation With CD28 and IL-6 Receptor Antagonists Status COMPLETED Phase PHASE1/PHASE2
NCT04063865 Everolimus Monotherapy as Immunosuppression After Liver Transplant Status TERMINATED Phase PHASE3
NCT03955172 Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection Status RECRUITING Phase NA
NCT03950609 Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03878524 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Status TERMINATED Phase PHASE1
NCT03839940 Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer Status TERMINATED Phase PHASE3
NCT03834740 A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection Status COMPLETED Phase EARLY_PHASE1
NCT03740334 Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03697408 Itacitinib + Everolimus in Hodgkin Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03659136 The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread Status COMPLETED Phase PHASE2
NCT03632317 A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Status WITHDRAWN Phase PHASE2
NCT03629847 Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue Status UNKNOWN Phase PHASE1/PHASE2
NCT03580239 Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency Status UNKNOWN Phase PHASE3
NCT03578432 Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy Status TERMINATED Phase EARLY_PHASE1
NCT03525834 Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. Status COMPLETED Phase PHASE4